Anticardiolipin antibodies and vascular access thrombosis in Taiwanese haemodialysis patients with chronic hepatitis C: A retrospective study

International Journal of Clinical Practice

Volumn 60, Issue 12, 2006, Pages 1591-1595

  Lee, C H ^a   Wang, I K ^a   Chen, T C ^a   Chang, H W ^b   Yang, C C ^a   Chien, Y S ^a   Wu, C S ^a   Chiou, T T Y ^a   Wu, M S ^a   Wang, P H ^b   Chuang, Feng Rong ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Anticardiolipin antibody; Chronic hepatitis C; Haemodialysis; Vascular access thrombosis

Indexed keywords

ANTICOAGULANT AGENT; CARDIOLIPIN ANTIBODY; ERYTHROPOIETIN; FOLIC ACID; IMMUNOGLOBULIN G;

ADULT; ANTIBODY TITER; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC NEPHROPATHY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SHUNT THROMBOSIS; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; TAIWAN; TREATMENT DURATION; VASCULAR ACCESS DEVICE;

ANTIBODIES, ANTICARDIOLIPIN; CATHETERS, INDWELLING; CROSS-SECTIONAL STUDIES; FEMALE; GRAFT OCCLUSION, VASCULAR; HEPATITIS C, CHRONIC; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RECURRENCE; RENAL DIALYSIS; RETROSPECTIVE STUDIES; THROMBOSIS;

EID: 33751003486     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.00857.x     Document Type: Article

References (21)

1. Hadziyannis SJ. The spectrum of extrahepatic manifestations in hepatitis C virus infection. J Viral Hepat 1997; 4: 9-28.
2. Al-Saeed A, Makris M, Malia RG et al. The developmental of antiphospholiplid antibodies in haemophilia is linked to infection with hepatitis C. Br J Haematol 1994; 88: 845-8.
3. Harada M, Fujisawa Y, Sakisaka S et al. High prevalence of anticardiolipin antibodies in hepatitis C virus infection: Lack of effects on thrombocytopenia and thrombotic complications. J Gastroenterol 2000; 35: 272-7.
4. Harris EN, Chan JKH, Asherson RA et al. Thrombosis, recurrent fetal loss, and thrombocytopenia: Predictive value of anti-cardiolipin antibody test. Arch Intern Med 1986; 146: 2153-6.
5. Gronhagen-Riska C, Teppo AM, Helentera A et al. Raised concentration of antibodies to cardiolipin in patients receiving dialysis. BMJ 1990; 300: 1696-7.
6. Garcia-Martin F, De Arriba G, Carrascosa T et al. Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease. Nephrol Dial Transplant 1991; 6: 543-7.
7. Page B, Yazbeck F, Zingraff J et al. Clotting of vascular access in dialysis patients associated to anticardiolipin antibodies. Nephrol Dial Transplant 1992; 7: 733 (Abstract).
8. Bala Subramanian V, Smith D, Mcmillan MA et al. Anticardiolipin antibodies in long-term dialysis patients. Nephrol Dial Transplant 1992; 7: 459 (Abstract).
9. Chew SL, Lins RL, Daelemans R et al. Are anticardiolipin antibodies clinically relevant in dialysis patients? Nephrol Dial Transplant 1992; 14: 1194-8.
10. Valeri A, Joseph R, Radhakrishnan J. A large prospective survey of anti-cardiolipin antibodies in chronic hemodialysis patients. Clin Nephrol 1999; 51: 116-21.
11. Prakash R, Miller CC, Suki WN. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis 1995; 26: 347-52.
12. Manns BJ, Burgess ED, Parsons HG et al. Hyperhomocyste-nemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Kidney Int 1999; 55: 315-20.
13. Haviv YS. Association of anticardiolipin antibodies with vascular access occlusion in hemodialysis patients: Cause or effect? Nephron 2000; 86: 447-54.
14. Dalekos GN, Achenbach K, Christodoulou D et al. Idiopathic dilated cardiomyopathy: Lack of association with hepatitis C virus infection. Heart 1998; 80: 270-5.
15. Dalekos GN, Christodoulou D, Kistis KG et al. A prospective evaluation of dermatologic side effects during alpha-interferon therapy for chronic viral hepatitis. Eur J Gastroenterol Hepatol 1998; 10: 933-9.
16. Matsuda J, Saitoh N, Gotoh M et al. High prevalence of anti-phospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-alpha. Am J Gastroenterol 1995; 90: 1138-41.
17. Prieto J, Yuste JR, Beloqui O et al. Anticardiolipin antibodies in chronic hepatitis C: Implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Hepatology 1996; 23: 199-204.
18. Jacq F, Emmerich J, Heron E et al. Distal gangrene and cryoglobulinemia related to hepatitis C virus infection with presence of anticardiolipin antibodies. Rev Med Interne 1997; 18: 324-7.
19. Malnick SD, Abend Y, Evron E et al. HCV hepatitis associated with anticardiolipin antibody and a ceredrovascular accident. Response to interferon therapy. J Clin Gastroenterol 1997; 24: 40-2.
20. Dalekos GN, Kistis KG, Boumba DS et al. Increased of anti-cardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenetic link to anti-phospholipid syndrome. Eur J Gastroenterol Hepatol 2000; 12: 67-74.
21. Zachou K, Liaskos C, Christodoulou DK et al. Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I cofactor or features of antiphospholipid syndrome. Eur J Clin Invest 2003; 33: 161-8.